RICHLAND, WASHINGTON – September 10, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced today that it will spotlight the growing cancer...
At Isoray, we recognize the value of industry conferences, specifically when it comes to continuing your education, staying up-to-date with the latest research, and networking with industry colleagues. Our team is looking forward to once again having the opportunity to join the radiation oncologist community at the ASTRO Annual Meeting to discuss the most recent developments in cancer treatment.
Isoray was proud to be a part of yet another annual meeting for the American Brachytherapy Society (ABS) in Miami and, as we’ve had some time to process all of the stimulating conversations and unique opportunities that ABS always provides, we’d like to highlight some of our favorite moments and discussions from this year’s event.
RICHLAND, WASHINGTON – August 13, 2019 – Studies recently reported at scientific meetings and published in medical journals illustrate that Isoray, Inc.'s (NYSE AMERICAN: ISR) Cesium Blu™ is making an important difference in providing treatment options for cancer...
New Brand Identity to Be Unveiled Thursday, June 13 RICHLAND, WASHINGTON – June 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced...
Record Revenue and Gross Profit Revenue Increased 22% Year-Over-Year RICHLAND, WASHINGTON – May 9, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body,...
Conference Call is May 9 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – May 1, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced that it...
Photo curtesy of The Boston Herald. Boston Herald Reporter Alexi Cohan recently joined Dr. Peter Orio on the “front lines” in order to learn more about brachytherapy for prostate cancer treatment. This article details the brachytherapy procedure process and the...
RICHLAND, WASHINGTON – April 16, 2019 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced a new training collaboration with Texas Oncology. The...
After nearly 10 years and more than 12,000 patients treated following its FDA approval for prostate cancer treatment, sufficient scientific data and patient-reported evidence suggest that Cesium-131 delivers equivalent to, or superior outcomes compared to Iodine and...
Transition concerns should not stop you from adding Cesium to your prostate brachytherapy practice. With a thoughtful approach to planning and the right support, you can seamlessly upgrade your prostate brachytherapy to the power of Cesium.
Record Revenue and Gross Profit Revenue Increased 24% Year-Over-Year RICHLAND, WASHINGTON - February 12, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...